Affordable Access

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.

Authors
  • Hamilton, A
  • Biganzoli, L
  • Coleman, R
  • Mauriac, L
  • Hennebert, P
  • Awada, A
  • Nooij, M
  • Beex, L
  • Piccart, M
  • Van Hoorebeeck, I
  • Bruning, P
  • de Valeriola, D
Type
Published Article
Journal
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Publication Date
Jun 01, 2002
Volume
13
Issue
6
Pages
910–918
Identifiers
PMID: 12123337
Source
Medline
License
Unknown

Abstract

The recommended dose of Caelyx/Doxil using this schedule is 60 mg/m2 every 6 weeks. This is a safe and effective regimen that permits prolonged administration of anthracycline to patients with metastatic breast cancer.

Report this publication

Statistics

Seen <100 times